Want to see PAVM full AI Analyst Report?
PAVM Stock Chart & Stats
$7.75
$0.11(1.44%)
At close: 4:00 PM EST
$7.75
$0.11(1.44%)
Day’s Range― - ―
52-Week Range$3.85 - $28.44
Previous Close$8
Volume99.04K
Average Volume (3M)377.79K
Market Cap
$39.66M
Enterprise Value$15.82
Total Cash (Recent Filing)$6.46M
Total Debt (Recent Filing)$17.01M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 18, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-37.69
Shares Outstanding7,159,034
10 Day Avg. Volume774,204
30 Day Avg. Volume377,786
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.13
Price to Sales (P/S)62.51
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$36.00Price Target Upside364.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.14
Revenue Forecast (FY)$490.00K
Bulls Say, Bears Say
Bulls Say
Recapitalization And Cleaner Capital StructureThe Series D and senior secured note eliminated prior convertibles and simplified ownership, reducing legacy dilution complexity. A cleaner cap table increases strategic flexibility to fund subsidiaries, negotiate partnerships, and pursue asset-level financing, improving the company's ability to execute over the medium term.
Meaningful Lucid Stake With Operational TractionA significant equity stake in a cash-generating subsidiary provides a durable asset and potential recurring fees or upside from Lucid's growth. Lucid's federal supply awards, VA orders and extended runway into 2027 offer a stabilizing income source and reduce consolidated cash flow pressure over time.
Veris Pilot Commercialization And Device Development ProgressActive clinical rollout and EHR integration create durable adoption pathways and data collection via a large registry, which supports reimbursement and commercialization. Ongoing device development with a planned regulatory submission and two-year battery objective strengthens the long-term product commercialization thesis.
Bears Say
Persistent Negative Profitability And Cash BurnRecurring negative gross profit and sustained operating losses indicate the core business currently does not generate cash. Persistent cash burn forces reliance on external capital for operations and development; absent consistent revenue and margin improvement, this undermines long-term self-sufficiency and increases execution risk.
Low Cash And Reliance On Milestone-contingent FinancingWith limited unrestricted cash, the company's near-term liquidity depends heavily on contingent events (LCD, FDA triggers) and exercise of warrants. These milestone-linked inflows create timing and execution risk; delays or failures would force dilutive financings or constrained operations, stressing medium-term continuity.
Historic Balance-sheet Volatility And High Leverage EpisodesPrior periods of negative equity and extreme leverage indicate a history of capital stress and refinancing. Even with TTM improvements, pronounced swings in assets, debt and equity raise the probability of future dilution or costly refinancing, increasing the company's long-run financing cost and strategic constraints.
PAVmed News
PAVM FAQ
What was PAVmed Inc’s price range in the past 12 months?
PAVmed Inc lowest stock price was $3.85 and its highest was $28.44 in the past 12 months.
What is PAVmed Inc’s market cap?
PAVmed Inc’s market cap is $39.66M.
When is PAVmed Inc’s upcoming earnings report date?
PAVmed Inc’s upcoming earnings report date is Aug 18, 2026 which is in 26 days.
How were PAVmed Inc’s earnings last quarter?
PAVmed Inc released its earnings results on May 15, 2026. The company reported -$4.42 earnings per share for the quarter, missing the consensus estimate of -$0.7 by -$3.72.
Is PAVmed Inc overvalued?
According to Wall Street analysts PAVmed Inc’s price is currently Undervalued.
Does PAVmed Inc pay dividends?
PAVmed Inc does not currently pay dividends.
What is PAVmed Inc’s EPS estimate?
PAVmed Inc’s EPS estimate is -0.47.
How many shares outstanding does PAVmed Inc have?
PAVmed Inc has 7,159,034 shares outstanding.
What happened to PAVmed Inc’s price movement after its last earnings report?
PAVmed Inc reported an EPS of -$4.42 in its last earnings report, missing expectations of -$0.7. Following the earnings report the stock price went up 1.24%.
Which hedge fund is a major shareholder of PAVmed Inc?
Currently, no hedge funds are holding shares in PAVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PAVmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (364.52% Upside)
$36.00 (364.52% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.02%
Trailing 12-Months
Company Description
PAVmed Inc
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
PAVM Stock 12 Month Forecast
Average Price Target
$36.00
▲(364.52% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
Co-Diagnostics
―
Tenon Medical, Inc.
―
Heart Test Laboratories, Inc.
―
Ownership Overview
13.42% Insiders
0.30% Mutual Funds
6.78% Other Institutional Investors
78.45% Public Companies and
Individual Investors